Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination

Clin Vaccine Immunol. 2016 Jun 6;23(6):524-529. doi: 10.1128/CVI.00026-16. Print 2016 Jun.

Abstract

HIV(+) subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bacterial / biosynthesis*
  • Antibodies, Bacterial / blood
  • Antiretroviral Therapy, Highly Active / adverse effects
  • CD4 Lymphocyte Count
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Infections / virology
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Male
  • Mice
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / microbiology
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / administration & dosage
  • Pneumococcal Vaccines / immunology*
  • Ritonavir / therapeutic use
  • Streptococcus pneumoniae / immunology*
  • Vaccination

Substances

  • Antibodies, Bacterial
  • HIV Protease Inhibitors
  • Immunoglobulin G
  • Immunoglobulin M
  • Pneumococcal Vaccines
  • Ritonavir